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A B S T R A C TObjectives: To evaluate the cost-effectiveness of competing gastro-
protective strategies, including single-tablet formulations, in the
prevention of gastrointestinal (GI) complications in patients with
chronic arthritis taking nonsteroidal anti-inﬂammatory drugs
(NSAIDs). Methods: We performed a cost-utility analysis to compare
eight gastroprotective strategies including NSAIDs, cyclooxygenase-2
inhibitors, proton pump inhibitors (PPIs), histamine-2 receptor antag-
onists, misoprostol, and single-tablet formulations. We derived esti-
mates for outcomes and costs from medical literature. The primary
outcome was incremental cost per quality-adjusted life-year gained.
We performed sensitivity analyses to assess the effect of GI compli-
cations, compliance rates, and drug costs. Results: For average-risk
patients, NSAID þ PPI cotherapy was most cost-effective. The NSAID/
PPI single-tablet formulation became cost-effective only when its
price decreased from €0.78 to €0.56 per tablet, or when PPI compliancesee front matter Copyright & 2013, International S
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F02.618), 3508 GA Utrecht, The Netherlands.fell below 51% in the NSAID þ PPI strategy. All other strategies were
more costly and less effective. The model was highly sensitive to the GI
complication risk, costs of PPI and NSAID/PPI single-tablet formulation,
and compliance to PPI. In patients with a threefold higher risk of GI
complications, both NSAID þ PPI cotherapy and single-tablet formula-
tion were cost-effective. Conclusions: NSAID þ PPI cotherapy is the
most cost-effective strategy in all patients with chronic arthritis irre-
spective of their risk for GI complications. For patients with increased GI
risk, the NSAID/PPI single-tablet formulation is also cost-effective.
Keywords: compliance, cost-effectiveness, cost-utility, dyspepsia,
gastrointestinal bleeding, nonsteroidal anti-inﬂammatory drugs,
proton pump inhibitors.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The prevalence of osteoarthritis and rheumatoid arthritis is high,
and the incidence of these chronic and expensive conditions is
rising. Empirical treatment for osteoarthritis and rheumatoid
arthritis often begins with nonsteroidal anti-inﬂammatory drugs
(NSAIDs) for symptom relief [1,2].
NSAIDs are associated with a wide spectrum of gastrointesti-
nal (GI) side effects, including dyspepsia, peptic ulcers, peptic
ulcer bleeding (PUB), and ulcer perforations. NSAIDs cause an
approximately three- to fourfold increase in these upper GI
complications [3]. GI complications are expensive; for example,
a Dutch observational study showed that for each €1.00 spent onNSAIDs, an additional €0.68 is needed for the treatment of GI
adverse events [4].
Gastroprotective agents (GPAs) can reduce GI complications of
NSAIDs, and are therefore widely recommended for use in high-
risk users [5]. Physicians can choose between several gastro-
protective strategies, including coprescription of NSAIDs with
acid-suppressive medication (proton pump inhibitors [PPIs] and
histamine-2-receptor antagonists [H2RAs]), misoprostol (prosta-
glandin analogue), or selective cyclooxygenase-2 inhibitors (cox-
ibs). Previous analyses revealed that PPI cotherapy is cost-
effective [6,7], especially in patients with a high risk of GI
complications. Several guidelines recommend PPI coprescription
for patients with moderate-to-high risk proﬁles [5,8]. The Nationalociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Fig. 1 – Decision model. The “M” is where the Markov model
was incorporated in the decision tree. H2RA, histamine-2-
receptor antagonist; NSAID, nonsteroidal anti-inﬂammatory
drug; OA, osteoarthritis; PPI, proton pump inhibitor; RA,
rheumatoid arthritis.
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recommend PPI coprescription in all patients on chronic NSAID
therapy [1]. H2RA may be cost-effective when used in high doses.
Only one study directly compared H2RA versus PPI cotherapy and
concluded that PPI cotherapy was more effective in healing ulcers
[9]. Misoprostol is also equally efﬁcacious to PPIs, although
common GI side effects (e.g., diarrhea and dyspepsia) reduce
compliance and possibly its effectiveness. Another alternative is
to replace nonselective NSAIDs with coxibs, which maintain anti-
inﬂammatory capability while reducing GI complications through
selective cox-2 inhibition [10,11]. Cost-effectiveness analyses
reveal that coxibs provide an acceptable cost-effectiveness ratio
compared with NSAID þ PPI combination therapy in high-risk
patients with a history of bleeding ulcers [12].
Although physicians are more aware than ever regarding the
clinical and economic burden of NSAIDs, adherence to prescrib-
ing guidelines for GPA use remained low; up to 60% of high-risk
patients are not prescribed adequate gastroprotection [13,14].
Furthermore, patient compliance with GPAs is inadequate, lead-
ing to suboptimal gastroprotection [15]. The risk of NSAID-related
GI complications increases by 16% for every 10% decrease in GPA
compliance [16].
Because of the low compliance with effective and cost-
effective GPAs, efforts have been made to enhance patient
adherence with prescribed therapies. In particular, new single-
tablet formulations (i.e., NSAID/PPI or NSAID/H2RA) have been
developed, which may limit poor clinical outcomes associated
with noncompliance by ensuring that GPA is administered with
each NSAID dose. Recent randomized controlled trials have
shown that both esomeprazole þ naproxen and ibuprofen þ
famotidine single-tablet formulation are superior to placebo in
reducing gastric ulcers [17,18]. Previous data also found that the
single-tablet formulation of diclofenac þ misoprostol is effective
in protecting patients at medium and high risk for GI complica-
tions [19].
To assist the clinical decision-making process for patients
with rheumatoid arthritis or osteoarthritis requiring chronic
NSAID treatment, we aimed to evaluate the costs and effective-
ness of eight different treatment strategies, including (co)pre-
scription of GPAs and single-tablet formulations while
accounting for patient compliance.Methods
Decision Model Framework
We developed a Markov model by using decision-analysis soft-
ware (TreeAge Pro 2009, TreeAge Software, Inc., Williamstown,
MA). We evaluated eight strategies for managing a hypothetical
cohort of 60-year-old patients with rheumatoid arthritis or osteo-
arthritis and requiring chronic NSAID therapy: 1) NSAID mono-
therapy (naproxen 500 mg b.i.d.); 2) NSAID þ PPI (naproxen 500
mg b.i.d. and omeprazole 20 mg q.d.); 3) NSAID/PPI single-tablet
formulation (naproxen 500 mg combined with esomeprazole 20
mg b.i.d.); 4) NSAID þ H2RA (naproxen 500 mg b.i.d. and
cimetidine 400 mg b.i.d.); 5) NSAID/H2RA single-tablet formula-
tion (ibuprofen 800 mg combined with famotidine 26.6 mg t.i.d.);
6) NSAID þ misoprostol (naproxen 500 mg b.i.d. and misoprostol
200 mg b.i.d.); 7) NSAID/misoprostol single-tablet formulation
(diclofenac 75 mg combined with misoprostol 200 mg b.i.d.); 8)
coxib monotherapy (celecoxib 100 mg b.i.d.) (Fig. 1). Coxib in
combination with PPI was left out of the model because no
literature is available for this strategy. The model tracked differ-
ential rates of compliance with these competing strategies, and
evaluated variations in compliance (Table 1). In our base-case
analysis, patients entering the model were 60 years old and didnot have any GI symptoms or a history of peptic ulcer disease.
Through a series of 3-month Markov transition cycles, we
followed the cohort over a 5-year time horizon. During each
cycle, patients could develop GI complications, including dyspep-
sia, ulcer complications (bleeding), and related mortality. After
these initial health states, patients either could become symptom
free, or go to a health state in which dyspepsia persists. In the
“dyspepsia persists” health state, patients had different costs
because of physician visits and medication, but comparable
utilities. If a patient got a PUB, he or she will thereafter transfer
to a “post” health state (post-PUB) in which he or she remained at
a higher risk for a recurrent event, had a different utility, and
higher health care costs compared with “no complications.” In a
post health state, the patient could still develop other complica-
tions (e.g., dyspepsia or recurrent PUB), yet he or she could never
return to a “nonpost” health state (Fig. 2).
Model Assumptions
We applied the following assumptions regarding physician and
patient behavior. To closely simulate clinical practice, we based
these assumptions on a combination of clinical guidelines and
expert opinion.1. If dyspepsia develops, patients ﬁrst visit their primary care
provider. Patients will be prescribed a 4-week trial of PPI
therapy. If dyspepsia persists despite this treatment, the
patient is referred to a gastroenterologist and undergoes
diagnostic endoscopic examination and testing for Helicobacter
pylori. In case of H. pylori positivity, a 1-week course of triple
therapy is prescribed and a 13C urea breath test is subse-
quently performed to conﬁrm H. pylori eradication.2. If dyspepsia persists in patients without endoscopic ﬁndings
or H. pylori negativity, patients visit their primary care pro-
vider again and receive another 3 months of PPI therapy.3. Patients presenting with GI bleeding visit the emergency
department and are admitted to the hospital. If necessary,
patients are stabilized with blood transfusion. A therapeutic
endoscopy is then performed. The patient is treated with
intravenous PPI therapy for 72 hours, followed by indeﬁnite
PPI therapy. Survivors are tested for H. pylori, and treated with
triple therapy if positive. If the bleeding recurs, a second
endoscopy is performed and endoscopic treatment is used if
Table 1 – Model parameters: probabilities for GI complications by treatment strategy based on 3-mo Markov
cycles.
Base-case
probability
Range tested in
sensitivity analysis
Reference
Average risk of death of 60-y-old with RA/OA 0.01 [20]
Probability to die of PUB 0.08 0.02–0.15 [21,22]
NSAID therapy
Probability to develop dyspepsia while on NSAID 0.13 0.05–0.29 [10,23–25]
Probability to develop PUB while on NSAID 0.004 0.001–0.005 [11,25–28]
NSAID þ PPI therapy
Probability to develop dyspepsia while on NSAID þ PPI 0.06 0.04–0.20 [29–31]
Probability to develop PUB while on NSAID þ PPI 0.002 0.0003–0.01 Assumption
Probability of PPI compliance in NSAID þ PPI users 0.68 0.2–1.0 [14–16]
NSAID þ H2RA therapy
Probability to develop dyspepsia while on NSAID þ H2RA 0.08 0.08–0.12 [30]
Probability to develop PUB while on NSAID þ H2RA 0.003 0.001–0.004 Assumption
Probability of H2RA compliance in NSAID þ H2RA users 0.68 0.3–1.0 [15,16]
NSAID þ misoprostol therapy
Probability to develop dyspepsia while on NSAID þ misoprostol 0.13 0.02–0.74 [30,31]
Probability to develop PUB while on NSAID þ misoprostol 0.0025 0.001–0.004 Assumption
Probability of misoprostol compliance in NSAID þ misoprostol users 0.33 0.3–1.0 [30,31]
Coxib therapy
Probability to develop dyspepsia while on coxib 0.095 0.04–0.11 [29,32]
Probability to develop PUB while on coxib 0.003 0.001–0.009 [27,28,33]
Utilities
Utility for dyspepsia 0.87 [34]
Utility for persisting dyspepsia 0.87
Utility for GI bleeding 0.82 [35]
Utility post-GI bleed 0.98 [6]
Utility for dyspepsia post-GI bleed 0.85
Utility for persisting dyspepsia post-GI bleed 0.85
Utility for no GI complications 1
Costs (€)
Embolization/surgery 1329.47 600–2000
3-mo NSAID 13.50 4.5–28.8
3-mo acetaminophen 21.42 9.57–21.42
3-mo PPI 20 mg 2.99 2–90
3-mo coxib 71.28 1–100
3-mo PPI 40 mg 6.13 3.98–90
3-mo NSAID/PPI single tablet 69.33 1–100
3-mo H2RA 23.58 11.26–35.90
3-mo misoprostol 175.92 100–200
3-mo NSAID/H2RA single tablet 70 1–100
3-mo arthrotec 66.65 1–100
Blood transfusion 405.35 200–600
Diagnostic endoscopy 343.79 175–525
GE visit 72 35–105
GP visit 28 10–35
Hospital admission 10 d 4570 2000–6000
HP test CLO 3.5 2–5
HP test breath 63.92 30–90
IV PPI 72 h 163.61 100–200
1 Month PPI 0.99 0.67–29
Therapeutic endoscopy 850 350–1200
Triple therapy 11.39 5–16
Additional probabilities
Probability for need of embolization/surgery 0.09 0.02–0.22 [36,37]
Probability to rebleed within 3 mo 0.067 0.05–0.09 [36,38]
Probability for ulcus ventriculi 0.18 0.11–0.24 [37]
Probability of need for blood transfusion 0.6 0.2–0.9 [36,37]
Probability of HP positive 0.48 0.42–0.92 [36,38]
Probability that dyspepsia resolves while on NSAID þ PPI 0.55 0.53–0.76 [39,40]
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Table 1 – continued
Base-case
probability
Range tested in
sensitivity analysis
Reference
Probability to develop dyspepsia post-GI bleed on acetominophen and PPI 0.05 0.01–0.07 Assumption
Probability that dyspepsia resolves post-GI bleed on acetominophen and PPI 0.61 00.55–0.68 [41,42]
Probability to rebleed post-GI bleed while on acetominophen and PPI 0.1 0.07–0.17 [31,43]
CLO, Campylobacter-like organism; Coxib, cyclooxygenase-2 inhibitor; GE, gastroenterologist; GI, gastrointestinal; GP, general practitioner; HP,
H. pylori; H2RA, histamine-2-receptor antagonist; IV, intravenous; NSAID, nonsteroidal anti-inﬂammatory drug; OA, osteoarthritis; PPI, proton
pump inhibitor; PUB, peptic ulcer bleeding; RA, rheumatoid arthritis.
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V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 6 9 – 7 7 7772needed. If endoscopic intervention fails, the patient under-
goes radiographic embolization or surgical intervention and
hospital stay is extended. If a patient has an ulcer bleeding
from a gastric ulcer, a second-look endoscopy will be per-
formed. Patients with GI bleeding will be converted to acet-
aminophen and a PPI for the remainder of the time horizon.4. Patients developing dyspepsia after a previous peptic ulcer
bleed ﬁrst visit their primary care provider, and are then
referred to a gastroenterologist to undergo diagnostic endo-
scopic examination and H. pylori testing. Patients testing
positive for H. pylori are treated with a 1-week course of triple
therapy and undergo breath testing to conﬁrm cure. PPI
therapy is then continued for the remainder of the time
horizon.
Clinical Probability Estimates
We performed a structured literature search in PubMed to
identify literature supporting our baseline probability estimates
for 30 clinical inputs (Table 1). If available, we relied on preexist-
ing systematic reviews and meta-analyses. If no data from
systematic reviews or meta-analyses were available, we selected
original articles. We aimed to collect data from studies that were
comparable in design, follow-up period, and study outcome. Our
base-case estimate was based on a sample-size weighted mean
of the absolute risks for the outcome extracted from the studies
we included. For variables that were not supported by published. 2 – Markov model structure; the cohort was followed
ough 3-month Markov cycles over a 5-year horizon. All
tients started in a health state in which they were free of
strointestinal complications. GI, gastrointestinal.data or if available data were conﬂicting, we made assumptions
about point estimates on the basis of expert opinion (two expert
gastroenterologists and one expert general practitioner) and
evaluation of other cost-effectiveness analyses on this subject
[6,7,19]. Because the precision of these estimates varies between
different populations, we varied each estimate over a wide range
in the sensitivity analysis.
Outcomes
We used quality-adjusted life-years (QALYs) as our effectiveness
outcome. The panel on cost-effectiveness in Health and Medicine
suggests that QALYs are the most appropriate unit for cost-
effectiveness analysis instead of clinical outcomes [44]. QALYs
account for both quantity and quality of life generated by health
care interventions. To calculate QALYs, we obtained seven
relevant health state utility values from the published literature
and incorporated these into the model (Table 1). Our overall
outcome was the incremental cost-effectiveness ratio (ICER)
evaluating differences in both costs and QALYs. We determined
a cost-effectiveness threshold of €20,000 per QALY gained follow-
ing Dutch national guidelines [45]. We discounted all utilities at
an annual rate of 3%, as recommended by the U.S. Panel on Cost-
Effectiveness in Health and Medicine [44].
Cost Estimates
For establishing cost estimates, we considered only direct med-
ical costs by using a third-party payer’s perspective. We present
all costs in euros. The costs of treating GI complications were
estimated on prices for physician services, endoscopic proce-
dures, and laboratory tests, derived from the Dutch Healthcare
Authority 2010 [46]. Costs of the medications studied in this
model were derived from the Health Care Insurance Board 2011
[47]. As with utilities, we discounted all at an annual rate of 3% as
recommended by guidelines [44].Sensitivity Analysis
To assess the inﬂuence of all variables in the model, we created a
tornado diagram to rank-order the most inﬂuential variables. We
performed one-way sensitivity analyses and reported thresholds in
which the relative order between strategies changed for the most
inﬂuential variables. To acknowledge the variability of probabil-
ities/risks between individual patients, we then performed a Monte
Carlo simulation (probabilistic sensitivity analysis) with 10,000
trials. We assumed triangular probability distributions around the
clinical probabilities, meaning that a parameter’s base-case value is
most likely to occur and the minimum and maximum values are
least likely to occur. We assumed that the mean value was equal to
the base-case point estimate. The base-case model assumed that
patients were at an average risk for developing a GI event from
NSAIDs. We also performed additional sensitivity analyses in
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 6 9 – 7 7 7 773patients at high risk for GI complications. Patients entered the
model with a base-case relative risk of 1.0 for GI complications of
NSAIDs, which could increase to a threefold higher relative risk for
GI complications. A high-risk patient illustrated a patient with a
threefold higher risk of GI complications. The threefold higher risk
could be a result of one or any combination of the following risk
factors: higher age, concomitant use of low-dose aspirin, anti-
coagulants, or steroids, or history of peptic ulcer disease [48]. We
subsequently plotted the results on a cost-effectiveness accept-
ability curve stratiﬁed by willingness-to-pay (WTP) thresholds for
patients with average- and high-risk proﬁles.Fig. 3 – The relative results of all strategies displayed in a
cost-effectiveness plane. Coxib, cyclooxygenase-2 inhibitor;
H2RA, histamine-2-receptor antagonist; ICER, incremental
cost-effectiveness ratio; NSAID, nonsteroidal anti-
inﬂammatory drug; PPI, proton pump inhibitor; QALY,
quality-adjusted life-year.Results
Base Case
NSAID þ PPI cotherapy was the most cost-effective strategy in the
base-case 60-year-old patient with chronic arthritis in need of
chronic NSAIDs. NSAID monotherapy was more expensive and
less effective in preventing GI complications compared with PPI
cotherapy, which rendered the latter a cost-saving approach.
Compared with separate NSAID þ PPI cotherapy, NSAID/PPI
single-tablet formulation costs an incremental €35,075 per addi-
tional QALY gained. All other strategies were outranked (domi-
nated, i.e., more expensive and less effective) by NSAID þ PPI
cotherapy (Table 2 and Fig. 3).
Sensitivity Analyses
The results of one-way sensitivity analysis (displayed in a tornado
diagram) show that our model was highly sensitive to the relative
risk of GI complications, the probability of PPI compliance, the
costs of PPIs and NSAID/PPI single-tablet formulation, and prob-
abilities for dyspepsia and PUB on NSAID þ PPI cotherapy (Fig. 4).
Table 3 provides the thresholds at which the cost-effectiveness of
the different strategies changed. For example, when compliance
with PPIs fell below 51% in the NSAID þ PPI cotherapy strategy,
the NSAID/PPI single-tablet formulation is preferred.
Higher GI Risk
Increasing the relative risk of GI complications from a base case
of 1.0 to 3.0 made NSAID/PPI single-tablet formulation increas-
ingly cost-effective, with its ICER falling to only €9917 versus
NSAID þ PPI combination therapy. The single-tablet formulation
became economically “viable” (i.e., ICER o €20,000) once the
relative risk of GI complications exceeded 1.7 times the average
risk. When the costs of PPIs exceeded €0.42/day or compliance toTable 2 – Base-case cost-effectiveness.
Strategy Average co
NSAID 1440
NSAID þ PPI 1103.5
NSAID/PPI single-tablet formulation 1764
NSAID þ misoprostol 2156
NSAID/misoprostol single-tablet formulation 1945
NSAID þ H2RA 1415
NSAID/H2RA single-tablet formulation 2074
Coxib 2188
Coxib, cyclooxygenase-2 inhibitor; H2RA, histamine-2-receptor antagon
anti-inﬂammatory drug; PPI, proton pump inhibitor; QALY, quality-adjus
 Compared with NSAID þ PPI.PPIs fell below 33%, NSAID þ PPI cotherapy became dominated
(i.e., both less effective and more expensive) by NSAID/PPI single-
tablet formulation. Other thresholds at which the relative order
of cost-effective strategies changed are displayed in Table 3. The
remaining strategies were however more expensive and less
effective than the above-mentioned alternatives (dominated).Probabilistic Sensitivity Analysis
By using Monte Carlo analysis, we compared strategies across
cohorts of 10,000 patients, each with different probabilities and risks.
Figure 5 and Figure 6 show the results on a cost-effectiveness
acceptability curve. For a WTP threshold of €20,000 per QALY gained,
the probability of being cost-effective was the highest for NSAID þ
PPI cotherapy users with 57%, followed by NSAID þ H2RA (17%) and
NSAID/PPI single-tablet formulation users (13%). The other strategies
had very low probabilities on being cost-effective. For high-risk
patients, these probabilities were 21%, 19%, and 42%, respectively.
If the WTP threshold was below €13,000, however, the probability of
being cost-effective was the highest for NSAID þ PPI cotherapy.st (€) Average QALY ICER
(euro/QALY)
4.27 Dominated
4.31 Reference
4.33 €35,075
4.27 Dominated
4.28 Dominated
4.29 Dominated
4.30 Dominated
4.30 Dominated
ist; ICER, incremental cost-effectiveness ratio; NSAID, nonsteroidal
ted life-year.
Fig. 4 – One-way sensitivity analysis: Tornado diagram. GE, gastroenterologist; GI, gastrointestinal; GP, general practitioner;
H2RA, histamine-2-receptor antagonist; NSAID, nonsteroidal anti-inﬂammatory drug; PPI, proton pump inhibitor; PUB, peptic
ulcer bleeding.
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In this cost-effectiveness analysis comparing different gastro-
protective treatment strategies for patients with chronic arthritis
using NSAIDs, we found that the combination of NSAID and PPITable 3 – Results one-way sensitivity analysis.
Variable Base-case
estimate
Range
tested
Average GI risk
% PPI compliance 68% 0.3–1.0
Cost PPI/tablet €0.03 0.02–1.0
Cost single-tablet formulation
NSAID þ PPI/d
€0.77 0.01–1.11
Probability of dyspepsia on
NSAID
0.13 0.04–0.20
Probability of dyspepsia on
NSAID þ PPI
0.06 0.02–0.20
High GI risk
% PPI compliance 68% 0.3–1.0
Cost PPI/tablet €0.03 0.02–1.0
Cost single-tablet formulation
NSAID þ PPI/d
€0.77 0.01–1.11
Probability of dyspepsia on
NSAID
0.13 0.04–0.20
Probability of dyspepsia on
NSAID þ PPI
0.06 0.02–0.20
GI, gastrointestinal; H2RA, histamine-2-receptor antagonist; NSAID, noncotherapy was not only a cost-effective strategy but also a cost-
saving strategy compared with all other studied strategies. These
results are based on a 60-year-old patient with an average-risk
proﬁle for GI complications (i.e., dyspepsia and/or PUB) in 5-year
follow-up. However, in patients with an increased GI risk (e.g.,Threshold Comment
51% If more than threshold, then the single-tablet
formulation NSAID/PPI and NSAID þ H2RA
cotherapy are cost-effective
€0.29 If less than threshold, then the single-tablet
formulation NSAID/PPI is cost-effective
€0.56 If less than threshold, then the single-tablet
formulation NSAID/PPI becomes cost-effective
0.20 If higher than threshold, then the single-tablet
formulation NSAID/PPI is cost-effective
0.12 If higher than threshold, then NSAID þ H2RA
cotherapy is cost-effective
79% If higher than threshold, then NSAID þ PPI
cotherapy is the only cost-effective option
33% If less than threshold, then NSAID þ PPI
cotherapy is dominated
€0.42 If higher than threshold, then NSAID þ PPI
cotherapy is dominated by the single-tablet
formulation NSAID/PPI
€1.07 If higher than threshold, then NSAID þ PPI
cotherapy is the only cost-effective strategy
0.09 If higher than threshold, then the single-tablet
formulation NSAID/PPI is cost-effective
0.12 If higher than threshold, then NSAID þ H2RA
cotherapy is cost-effective
steroidal anti-inﬂammatory drug; PPI, proton pump inhibitor.
Fig. 5 – Cost-effectiveness acceptability curves showing the
probability of being most effective at different WTP
thresholds in average-risk patients. Coxib, cyclooxygenase-
2 inhibitor; H2RA, histamine-2-receptor antagonist; NSAID,
nonsteroidal anti-inﬂammatory drug; PPI, proton pump
inhibitor; WTP, willingness to pay.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 6 9 – 7 7 7 775previous GI bleed, anticoagulant and/or steroids use), both NSAID
þ PPI cotherapy and NSAID/PPI single-tablet formulation were
the preferred strategies. With an ICER of €9917 compared with
NSAID þ PPI cotherapy, the NSAID/PPI single-tablet formulation
was optimally cost-effective assuming the WTP threshold was
held at €20,000 per QALY. We found that compliance to PPIs
affected the cost-effectiveness of the different strategies. If
compliance to PPI is low (o51%) in average-risk patients, the
NSAID/PPI single-tablet formulation also becomes a cost-effective
strategy. In contrast, in high-risk patients with a high compliance
(479%), NSAID þ PPI cotherapy is the only cost-effective strategy.
Other inﬂuential variables included the costs of PPI and of the
NSAID/PPI single-tablet formulation, and probabilities for dys-
pepsia on NSAID and NSAID þ PPI cotherapy.
This is the ﬁrst model to demonstrate that NSAID and PPI
coprescription is potentially cost-saving compared with other
strategies, including NSAID monotherapy. This ﬁnding supports
the National Institute for Health and Clinical Excellence guide-
lines to use GPA cotherapy in all patients on chronic NSAID
therapy. In a previously published cost-effectiveness analysis,
Latimer et al. [6] also concluded that PPI cotherapy was cost-
effective (ICER €1175) for 55-year-old patients with osteoarthritisFig. 6 – Cost-effectiveness acceptability curves showing the
probability of being most effective at different WTP
thresholds in high-risk patients. Coxib, cyclooxygenase-2
inhibitor; H2RA, histamine-2-receptor antagonist; NSAID,
nonsteroidal anti-inﬂammatory drug; PPI, proton pump
inhibitor; WTP, willingness to pay.taking traditional NSAIDs with an average risk of GI complica-
tions. Our results are however not in line with publications by
Spiegel et al. [7] and Cameron et al. [49], which concluded that
NSAID monotherapy was the preferred strategy in average-risk
patients taking NSAIDs. An explanation for these conﬂicting
results can be found in differences in the model structure, and
in the utilities and probabilities used for the model input. But
maybe more important are the costs of PPIs that have decreased
signiﬁcantly over the last few years because of generic avail-
ability. Spiegel et al., Al et al., and Cameron et al. used PPI costs
ranging from €0.22 to €2.52, which resulted in less beneﬁt for the
strategies combining NSAIDs with PPIs. This was also supported
by our sensitivity analysis in which we found that for average-
risk patients the costs of PPIs should be below €0.29 and for high-
risk patients below €0.42. Latimer used a cost of €0.08 for PPIs per
day, which also resulted in cost-effectiveness for all NSAID users,
and our PPI costs are even lower (€0.03) [6,7,12,19,49]. And we also
incorporated compliance and single-tablet formulations in the
model, which gives a better and closer reﬂection of clinical
practice nowadays.
Estimations on compliance were derived from the literature,
though little is known about the compliance to misoprostol and
H2RAs. We made assumptions for compliance to H2RAs and
misoprostol on the basis of the best available literature and
veriﬁed these assumptions with an expert panel. Despite the
potential inaccuracy of the point estimates for these values, we
found that our basic results did not change even after ranging
compliance estimates for H2RA and misoprostol over a wide
range. By using sensitivity analyses, we were able to rank order
the studied strategies and assess how differences in compliance
rates inﬂuence our results. Compliance rates differ both on a
population level and on a patient level. Van Soest et al. recently
showed that compliance with PPIs and NSAIDs in The Nether-
lands was higher (81%) compared with the compliance rates in
the United Kingdom (72%) and Italy (58%) [49]. Moreover, Gold-
stein et al. found a compliance rate of 68% in the United States,
whereas another Dutch cohort calculated a GPA compliance rate
of 63% [21,22]. On an individual patient level, estimating com-
pliance remains challenging. Potential predictors of low compli-
ance include duration of therapy, indication of therapy
(preventive vs. disease controlling), gender, and dosing regimen
(less frequent dosing results in higher compliance rates) [50,51]. A
good proﬁle for GPA compliance, however, has not yet been
developed.
Our model has several strengths. First, we built an extensive
model and incorporated two clinically meaningful end points,
that is, dyspepsia and GI bleeding. Second, we accounted for
compliance with GPAs; to our knowledge, this has not been
incorporated into previous models. Some other models incorpo-
rated the probability of being intolerant to misoprostol; however,
they did not incorporate probabilities for being compliant to all
different strategies [19]. Compliance appeared to highly affect the
cost-effectiveness of different strategies in our model. We also
integrated new strategies of single-tablet formulations in the
model. Nonetheless, little is known about these single-tablet
formulations with regard to compliance. Finally, we performed
our analysis for both average-risk patients and increased risk
patients (i.e., threefold higher risk), making our results more
applicable to all NSAID users. This increased risk population can
be identiﬁed by guidelines developed on this subject in whom
patients are stratiﬁed toward increased risk and low risk [5,8].
Our study also has important limitations. We derived proba-
bility estimates used in the model from heterogeneous studies.
Different patient groups, follow-up periods, and quality of data
make it difﬁcult to precisely estimate the mean probability. To
correct for that, we used systematic reviews and meta-analyses
where possible. Furthermore, several probabilities could not be
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 6 9 – 7 7 7776derived from the literature or were supported by only a few
studies. For example, little data are available that compared the
risk of GI bleeding between coxib and NSAID þ PPI cotherapy. To
account for these uncertainties, we performed probabilistic sen-
sitivity analyses across a wide range for each key variable in the
model. We found that the model was highly sensitive to the
probabilities of dyspepsia in each arm. We therefore veriﬁed
these probabilities with published data and previous cost-
effectiveness studies [6,7,19,49]. Probabilistic sensitivity analyses
were also used to account for differences in drug and other health
care costs between different health care systems. Subsequently,
we did not include side effects of the gastroprotective strategies
or NSAIDs in our model because literature is limited and con-
ﬂicting. Overall, we still believe that it is important not to forget
to treat patients on an individual patient level and although we
did perform sensitivity analyses with the input of our model to
account for uncertainties, we were not able to include all patient
characteristics in the model. We would apply our results to a
population without any contraindications for PPI use. Moreover,
it is possible that NSAID use in clinical practice is more on
demand instead of continuous, yet patients with osteoarthritis or
rheumatoid arthritis are likely to use NSAIDs chronically. Chronic
therapy ﬁts a Markov model perfectly, where intermittent use is
less appropriate. Therefore, caution is warranted if our results are
extrapolated to all NSAID users. In addition, we did not account
for the possibility that patients are noncompliant to their NSAIDs
as well as their GPAs. Yet, we assumed good compliance to
NSAIDs because patients use this medication for pain relief.
In conclusion, NSAID þ PPI cotherapy is a cost-saving strategy
for patients with chronic arthritis at average or high risk of GI
complications, considering compliance. The NSAID/PPI single-
tablet formulation is an additional option for average-risk
patients with low compliance or if the costs of PPIs are higher,
and is also a cost-effective strategy for high-risk patients. Com-
pliance to PPI was found to be an important and inﬂuential factor,
for both average- and high-risk patients.
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